![Chi Lin Kuo](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Network origin in Chi Lin Kuo first degree
Entity | Entity type | Industry | |
---|---|---|---|
V-Bio Ventures BV
![]() V-Bio Ventures BV Investment ManagersFinance V-Bio Ventures BV is an Independent Venture Capital firm founded in 2015 by Christina Takke and Willem Broekaert. V-Bio Ventures BV is headquartered in Ghent.
6
| Private Company | Investment Managers | 6 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Chi Lin Kuo via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
V-Bio Management 1 BV
![]() V-Bio Management 1 BV Financial ConglomeratesFinance Part of V-Bio Ventures BV, V-Bio Management 1 BV functions as an investment holding Belgian company. The company is based in Ghent, Belgium. | Financial Conglomerates | Director/Board Member Director/Board Member | |
ARGENX SE | Pharmaceuticals: Other | Director/Board Member | |
Candriam Belgium SA
![]() Candriam Belgium SA Investment ManagersFinance Candriam Belgium SA (Candriam) is the Belgian asset management subsidiary of Candriam Luxembourg SCA, ultimately held by New York Life Insurance Co. in the US. Founded in 1998, the firm was formerly known as Dexia Asset Management Belgium SA, the asset management division of Dexia SA (XB: DEXB). In 2014, New York Life Investments acquired Dexia Asset Management and the firm changed their name to Candriam, which is an acronym of their core values: “Conviction and Responsibility in Asset Management”. Headquartered in Brussels, Candriam provides discretionary and non-discretionary investment advisory services to US registered funds, a limited number of US natural persons, and to institutions. | Investment Managers | Analyst-Equity | |
Dualyx NV
![]() Dualyx NV Miscellaneous Commercial ServicesCommercial Services Dualyx NV is a biotech company based in Ghent, Belgium that focuses on developing novel Treg-based therapies for patients with difficult-to-treat autoimmune diseases. The CEO of the company is Wouter Verhoeven, and it is located in Zwijnaarde, Belgium. Dualyx has developed a pipeline of highly promising immune modulating programs, including DT-001, an antibody agonist program targeting the TNF receptor 2 (TNFR2), which is currently in IND-enabling studies. The Belgian company aims to create next-generation biologic drugs for autoimmunity therapies with novel mechanisms of action, lower toxicity, and improved patient outcomes than traditional therapeutics. The company was founded in 2020 by Luc van Rompaey in collaboration with Wurzburg University, Argenx, VIB, Ghent University, and KU Leuven. | Miscellaneous Commercial Services | Director/Board Member | |
AgomAb Therapeutics NV
![]() AgomAb Therapeutics NV Miscellaneous Commercial ServicesCommercial Services AgomAb Therapeutics NV operates as a Belgian biotherapeutics company, developing agonistic antibodies for regeneration of damaged tissues. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium. | Miscellaneous Commercial Services | Director/Board Member | |
Advitos GmbH
![]() Advitos GmbH Medical SpecialtiesHealth Technology Advitos GmbH manufactures, develops, and markets liver support therapy devices. Its therapy device helps enhance the survival of patients with life-threatening liver diseases. The company was founded by Dr. Bernhard Kreyman in 2005 and is headquartered in Munich, Germany. | Medical Specialties | Director of Finance/CFO | |
Clearstream Banking AG
![]() Clearstream Banking AG Regional BanksFinance Clearstream Banking AG engages in providing commercial banking services. Its services include settlement, custody, global securities, financing, investment fund, business and IT solutions and customer support. The company is headquartered in Eschborn, Germany. | Regional Banks | Corporate Officer/Principal | |
Syndesi Therapeutics SA
![]() Syndesi Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium. | Miscellaneous Commercial Services | Director/Board Member | |
Confo Therapeutics NV
![]() Confo Therapeutics NV Pharmaceuticals: MajorHealth Technology Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium. | Pharmaceuticals: Major | Director/Board Member | |
Precirix NV
![]() Precirix NV Pharmaceuticals: MajorHealth Technology Precirix NV develops and distributes radio-immunotherapeutic drugs for cancer patients. The company was founded on October 14, 2014 by Jens De Vos, Ludwig Camusot, Nick Devoogdt, Geert Raes, Tony Lahoutte and Matthias Dhuyvetter and is headquartered in Brussels, Belgium. | Pharmaceuticals: Major | Director/Board Member | |
Roche Glycart AG
![]() Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
PIERIS PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member | |
Amakem NV
![]() Amakem NV Medical/Nursing ServicesHealth Services Amakem NV operates as a biopharmaceutical company. It uses kinase inhibitors for treatments of bowel, eye, and lung diseases. The company was founded by Jack Elands, Dirk Leysen, Olivier Raynald Defert, and Nadya Kaval on July 22, 2009 and is headquartered in Diepenbeek, Belgium. | Medical/Nursing Services | Director/Board Member | |
Technische Universität Darmstadt | College/University | Graduate Degree | |
Université Catholique de Louvain | College/University | Doctorate Degree | |
Universität zu Köln | College/University | Doctorate Degree | |
Polpharma Biologics Utrecht BV
![]() Polpharma Biologics Utrecht BV Miscellaneous Commercial ServicesCommercial Services Polpharma Biologics Utrecht BV operates as a biopharmaceutical research and development company. It specializes in the development of monoclonal antibodies generation, cell line, upstream process, downstream process, analytical, and bioassay development services. The company is headquartered in Utrecht, the Netherlands. | Miscellaneous Commercial Services | Director/Board Member | |
Forbion Capital Partners Management Holding BV
![]() Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Private Equity Investor | |
OCTIMET Oncology NV
![]() OCTIMET Oncology NV BiotechnologyHealth Technology OCTIMET Oncology NV develops MET kinase inhibitors for the treatment of cancer. The company was founded by Timothy Perera, Ann Louise Meulemans, Paolo Comoglio, and Philip Owen in 2016 and is headquartered in Beerse, the Netherlands. | Biotechnology | Chief Executive Officer | |
Gadeta BV
![]() Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands. | Medical Specialties | Director of Finance/CFO | |
The Chartered Institute of Management Accountants
![]() The Chartered Institute of Management Accountants Other Consumer ServicesConsumer Services The Chartered Institute of Management Accountants, also known as aicpa® & cima®, is a global organization with 689,000 members, students, and professionals. The non-profit company is based in London, UK, and has a global presence of subsidiaries in several regions. The British company advocates for the accounting and finance profession, as well as the public interest and business sustainability. Andrew Harding has been the CEO of the company since 2009. | Other Consumer Services | Corporate Officer/Principal | |
MERUS N.V. | Biotechnology | Director of Finance/CFO | |
ABATTOIR N.V. | Food: Meat/Fish/Dairy | Director/Board Member | |
Horama SA
![]() Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France. | Biotechnology | Director/Board Member | |
CropDesign NV
![]() CropDesign NV Miscellaneous Commercial ServicesCommercial Services CropDesign NV develops traits for cereal crops. It delivers agronomic traits for the global commercial seed markets. The firm focuses on enhancing grain yield in crops such as corn and rice, and increasing biomass of energy crops. Its platform, TraitMill, lows evaluating the effect of genes on the performance of plants under different growing conditions, including drought and low nutrient stress. The company was founded in 1998 and is headquartered in Zwijnaarde, Blgium. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer | |
Augustine Therapeutics NV
![]() Augustine Therapeutics NV Medical/Nursing ServicesHealth Services Augustine Therapeutics NV is a Belgian company that focuses on developing innovative therapies for neuromuscular and neurodegenerative diseases. The company is based in Leuven, Belgium. The company's main focus is on HDAC6, a class II histone deacetylase, which is a well-known molecular target in various diseases, particularly neurodegenerative disorders and neuropathies. The company was founded in 2019, and Sylvain Celanire has been the CEO of the company since 2020. | Medical/Nursing Services | Director/Board Member |
Statistics
International
Belgium | 15 |
Netherlands | 7 |
Germany | 6 |
Switzerland | 2 |
United States | 2 |
Sectoral
Health Technology | 13 |
Commercial Services | 7 |
Finance | 5 |
Consumer Services | 5 |
Health Services | 3 |
Operational
Director/Board Member | 17 |
Private Equity Investor | 6 |
Corporate Officer/Principal | 5 |
Director of Finance/CFO | 4 |
Founder | 3 |
Most connected contacts
Insiders | |
---|---|
Christina Takke | 14 |
Willem Broekaert | 7 |
Shelley Margetson | 6 |
Katja Rosenkranz | 5 |
Ward Capoen | 3 |
Rishabh Chawla | 1 |
- Stock Market
- Insiders
- Chi Lin Kuo
- Company connections